| Dr Tulio Q Estrada-quintero, MD | |
|
428 S Main St, Greenville, PA 16125-1748 | |
| (724) 588-9830 | |
| (724) 588-9860 |
| Full Name | Dr Tulio Q Estrada-quintero |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 43 Years |
| Location | 428 S Main St, Greenville, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649258310 | NPI | - | NPPES |
| 0015135010004 | Medicaid | PA | |
| 110123509 | Other | PA | RR MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD053235L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Upmc Horizon | Greenville, PA | Hospital |
| Upmc Jameson | New castle, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Pittsburgh Physicians | 8729990239 | 3721 |
News Archive
In March 2020, not long after the first cases of COVID-19 were reported locally, health officials in the city of St. Louis and St. Louis County issued emergency public health orders intended to reduce interactions between people and slow the transmission of the novel respiratory virus.
Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.
Cardiome Pharma Corp. today announced that its subsidiary, Cardiome Development AG, has entered into an agreement with LifePharma (Z.A.M) Ltd., to sell and distribute BRINAVESS (vernakalant intravenous) exclusively in Cyprus.
Exposure to conflicting news about the health benefits of certain foods, vitamins and supplements often results in confusion and backlash against nutrition recommendations, finds a recent study in the Journal of Health Communication: International Perspectives.
After menopause, 6 to 10 million women take hormone therapies, which are often a combination of estrogen and progestin, to replace hormones lost from inactive ovaries. Progestin is a hormone that is used to counteract the potentially negative effects of estrogen therapy on the uterus. In studies sponsored by the National Institutes of Health, evidence has been found that estrogen and progestin in hormone therapies increase the risk of breast cancer in post-menopausal women.
› Verified 6 days ago
| Entity Name | University Of Pittsburgh Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619935004 PECOS PAC ID: 8729990239 Enrollment ID: O20040308000883 |
News Archive
In March 2020, not long after the first cases of COVID-19 were reported locally, health officials in the city of St. Louis and St. Louis County issued emergency public health orders intended to reduce interactions between people and slow the transmission of the novel respiratory virus.
Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.
Cardiome Pharma Corp. today announced that its subsidiary, Cardiome Development AG, has entered into an agreement with LifePharma (Z.A.M) Ltd., to sell and distribute BRINAVESS (vernakalant intravenous) exclusively in Cyprus.
Exposure to conflicting news about the health benefits of certain foods, vitamins and supplements often results in confusion and backlash against nutrition recommendations, finds a recent study in the Journal of Health Communication: International Perspectives.
After menopause, 6 to 10 million women take hormone therapies, which are often a combination of estrogen and progestin, to replace hormones lost from inactive ovaries. Progestin is a hormone that is used to counteract the potentially negative effects of estrogen therapy on the uterus. In studies sponsored by the National Institutes of Health, evidence has been found that estrogen and progestin in hormone therapies increase the risk of breast cancer in post-menopausal women.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tulio Q Estrada-quintero, MD 428 South Main Street, Greenville, PA 16125 Ph: (724) 588-9830 | Dr Tulio Q Estrada-quintero, MD 428 S Main St, Greenville, PA 16125-1748 Ph: (724) 588-9830 |
News Archive
In March 2020, not long after the first cases of COVID-19 were reported locally, health officials in the city of St. Louis and St. Louis County issued emergency public health orders intended to reduce interactions between people and slow the transmission of the novel respiratory virus.
Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.
Cardiome Pharma Corp. today announced that its subsidiary, Cardiome Development AG, has entered into an agreement with LifePharma (Z.A.M) Ltd., to sell and distribute BRINAVESS (vernakalant intravenous) exclusively in Cyprus.
Exposure to conflicting news about the health benefits of certain foods, vitamins and supplements often results in confusion and backlash against nutrition recommendations, finds a recent study in the Journal of Health Communication: International Perspectives.
After menopause, 6 to 10 million women take hormone therapies, which are often a combination of estrogen and progestin, to replace hormones lost from inactive ovaries. Progestin is a hormone that is used to counteract the potentially negative effects of estrogen therapy on the uterus. In studies sponsored by the National Institutes of Health, evidence has been found that estrogen and progestin in hormone therapies increase the risk of breast cancer in post-menopausal women.
› Verified 6 days ago
James Perry, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 90 Shenango St, Greenville, PA 16125 Phone: 724-588-4240 | |
Victor Colaiaco, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 90 Shenango St, Greenville, PA 16125 Phone: 724-588-4240 | |
Dr. Troy A Jones, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 90 Shenango St, Greenville, PA 16125 Phone: 724-588-4240 Fax: 724-588-0198 | |
Todd Jones, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 90 Shenango St, Greenville, PA 16125 Phone: 724-588-4240 |